Vitamin D (25-hydroxy)

You have probably heard that vitamin D matters, but the number that tells you where you actually stand is 25(OH)D (25-hydroxyvitamin D). This is the form of vitamin D your body stores after sunlight, food, and supplements are processed by your liver, and it is the single blood marker guideline bodies agree best reflects your true vitamin D status.

The stakes are real. Low levels have been associated with weaker bones and, in large European and UK Biobank studies, meaningfully higher risk of dying from any cause and from heart disease. It is worth noting that the 2024 Endocrine Society guideline recommends against routine 25(OH)D screening in generally healthy adults, and the US Preventive Services Task Force concluded there is insufficient evidence for or against screening in asymptomatic adults. Testing is most useful for people in groups where results are likely to change management, such as those with bone disease, malabsorption, chronic kidney disease, or clinical suspicion of deficiency.

What This Test Measures

Vitamin D is not one molecule but a small family. Your skin produces vitamin D3 after UVB sunlight hits a cholesterol-derived precursor. You also get vitamin D2 and D3 from food and supplements. Both forms travel to your liver, where an enzyme called CYP2R1 converts them into 25(OH)D, the storage form measured by this test.

Because 25(OH)D has a half-life of about two to three weeks in tracer studies, its concentration is stable enough to represent your cumulative vitamin D supply rather than what you did yesterday. (Apparent half-life can be much longer when starting from very high levels, likely reflecting mobilization from body stores.) It is also the immediate raw material your kidneys use to make the fully active hormone (1,25-dihydroxyvitamin D). Most 25(OH)D circulates bound to a carrier called vitamin D-binding protein, with roughly 85 to 90% on that carrier, another 10 to 15% on albumin, and only about 0.03% floating freely.

This test uses an immunoassay, an antibody-based method that measures total 25(OH)D. Immunoassays are fast, widely available, and precise enough for routine monitoring. Their limitations, discussed below, show up mostly at decision thresholds, in people taking vitamin D2, and in specific medical situations.

Bone Health and Fractures

The oldest and strongest link is skeletal. Very low 25(OH)D is associated with increased risk of rickets in children and osteomalacia in adults, both diseases of impaired bone mineralization. Higher levels within the sufficient range appear safe and adequate for skeletal health in the general adult population.

Beyond severe deficiency, lower 25(OH)D is consistently tied to worse bone mineralization, higher falls risk, and higher fracture risk in observational studies. Randomized evidence is more mixed: the largest 2026 meta-analysis (69 trials, 153,902 participants) found that vitamin D supplementation had little to no effect on fractures (RR 1.00, 95% CI 0.95 to 1.06) or falls (RR 0.97, 95% CI 0.91 to 1.03) in adults not on osteoporosis treatment, and the VITAL trial showed no fracture or fall reduction in the general adult population. The clearest interventional benefits come from combined calcium plus vitamin D in institutionalized or deficient older adults, not from supplementation across unselected healthy populations.

All-Cause and Cardiovascular Mortality

The largest signal outside bone is mortality. In a European consortium analysis of 26,916 adults using standardized measurement, people with 25(OH)D in the lowest category were roughly 67% more likely to die during follow-up than those in the reference range. Those in intermediate low bands had about 33% and 15% higher risk. The pattern for cardiovascular mortality mirrored all-cause mortality, and Mendelian randomization work in UK Biobank supports a causal contribution of very low 25(OH)D to mortality risk.

In UK Biobank, this risk curve appeared to level off around 60 nmol/L for total and cardiovascular mortality. In other words, the biggest gains are moving out of the deficient range, not pushing to very high levels. That said, large randomized trials of vitamin D supplementation (VITAL, ViDA, D-Health) have generally not shown a significant reduction in all-cause mortality in unselected populations, so correcting low 25(OH)D to reduce mortality remains supported by observational and genetic evidence rather than proven by trials.

Cardiovascular Disease Events

A meta-analysis of prospective studies found that every 10 ng/mL higher 25(OH)D was tied to about 10% lower risk of any cardiovascular event and 12% lower risk of cardiovascular death. A separate meta-analysis found people in the lowest category of 25(OH)D had roughly 52% higher risk of any cardiovascular disease and 64% higher risk of stroke compared with the highest category.

In adults with prediabetes, one UK Biobank analysis showed those with higher 25(OH)D had substantially lower risk of cardiovascular events, heart failure, cardiovascular death, and all-cause death compared with those in the lowest category. These are association data, and randomized trials of supplementation have not translated them into a cardiovascular benefit. The VITAL trial (HR 0.97, 95% CI 0.85 to 1.12), the ViDA trial, and a meta-analysis of 21 randomized trials in over 83,000 people (RR 1.00, 95% CI 0.95 to 1.06 for major cardiovascular events) all showed null results, and the D-Health trial found a borderline, non-significant trend. Low 25(OH)D is a real risk marker, but current interventional evidence does not show that raising it lowers cardiovascular events.

Type 2 Diabetes and Metabolic Risk

In pooled prospective data, people in the highest category of 25(OH)D had about 38% lower risk of developing type 2 diabetes compared with the lowest, with each 10 nmol/L increment tied to roughly 4% lower risk. Low 25(OH)D also tracks with metabolic syndrome and insulin resistance.

The catch is that giving vitamin D to already deficient people with prediabetes or diabetes has not clearly cut mortality or major cardiovascular events in randomized trials. That suggests low 25(OH)D is partly a marker of underlying metabolic and lifestyle risk, not just a modifiable cause of it.

Immune and Autoimmune Conditions

Low 25(OH)D is associated with higher rates of several immune-mediated conditions, including psoriasis, type 1 diabetes, multiple sclerosis, rheumatoid arthritis, tuberculosis, and respiratory infections. The active form of vitamin D acts through receptors on many immune cells.

Supplementation trials have been mixed. A large UK test-and-treat trial (CORONAVIT) found no reduction in acute respiratory tract infections or COVID-19 in the general adult population. In hospitalized COVID-19 patients, calcifediol improved lymphocyte counts and lowered the neutrophil-to-lymphocyte ratio, but hospitalization and mortality differences were not statistically significant. So while the associations are real, the case for testing and treating specifically to prevent infection outside of true deficiency remains unproven by randomized trials.

Why One Reading Is Not Enough

A single 25(OH)D result is a snapshot, not a trend. Your levels shift with season, sun exposure, supplement use, and body composition. Because 25(OH)D has a two-to-three-week half-life, changes in behavior take one to three months to fully register in the blood. Any decision about supplementation is stronger if it is based on two or more measurements.

There is also a technical reason to track over time on the same platform. Immunoassays can disagree with the gold-standard method by clinically meaningful amounts, so switching labs mid-course can look like a change when nothing has actually shifted in your body. Keeping your testing on one method gives you a cleaner signal.

A practical cadence: get a baseline, retest three to six months after any change to sun habits or supplements, and then at least once a year. If you are actively correcting a deficiency, retest at three months to confirm your regimen is working. If you are near the low end of the sufficient range in winter, a repeat in the opposite season shows you your natural swing.

When Results Can Be Misleading

Immunoassay results are useful but not perfect. Automated immunoassays vary from one platform to another, and comparison studies show they misclassify vitamin D status in a meaningful fraction of samples relative to reference LC-MS/MS methods. The biggest problems cluster around the following situations.

• Vitamin D2 supplementation: many immunoassays under-detect the D2 form. If you take a high-dose D2 prescription (ergocalciferol), a routine immunoassay result can look low even when your true total vitamin D is adequate.
• Pregnancy, oral contraceptives, and estrogen therapy: these raise vitamin D-binding protein, which can push total 25(OH)D higher on some immunoassays without changing the biologically active fraction. In one study three different assays disagreed markedly in pregnant patients while agreeing in non-pregnant controls.
• Acute or critical illness: systemic inflammation lowers vitamin D-binding protein and can drop total 25(OH)D, so a low result in the hospital may partly reflect the illness rather than long-term stores.
• Switching labs or platforms: even well-standardized immunoassays can disagree by amounts large enough to reclassify sufficient as deficient or the reverse. Stick with one platform when tracking trends.

None of these is a reason to avoid the test. They are reasons to interpret a borderline number in context, and to confirm surprising results with a repeat or, in complex cases, a reference-method (LC-MS/MS) measurement.

What To Do With An Out-of-Range Result

If your 25(OH)D comes back low, the next step is not to guess a dose. It is to add the companion tests that tell you whether your calcium and bone biology are actually being affected. Intact parathyroid hormone (PTH) rises when 25(OH)D is functionally low, and pairing the two gives a stronger picture than either alone. Serum calcium, phosphorus, and kidney function help rule out disorders of vitamin D metabolism such as chronic kidney disease or granulomatous disease.

For a very high result, especially above the range explained by your supplementation, the pathway is different. Repeat the measurement (ideally by LC-MS/MS), check serum calcium, and consider whether a granulomatous condition, unusual over-supplementation, or an assay artifact is at play. Persistently high 25(OH)D with high calcium warrants specialist evaluation.

For results in the borderline-low range, the practical questions are how far you are from the deficient threshold, whether your diet and sun exposure explain it, and whether you are in a group (older adults, darker skin at higher latitude, obesity, pregnancy) where empiric supplementation is generally reasonable. That last decision is a conversation for your clinician, informed by your number, not driven by it in isolation.